Kuznicki Law PLLC is investigating the proposed sale of Cancer Prevention Pharmaceuticals, Inc. to Panbela Therapeutics, Inc. (“the Company”) (NasdaqCM: PBLA). Under the terms of the proposed transaction, holders of Panbela common stock are expected to own only approximately 59% of the post-merger holding company.
If you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, contact us toll free at 833-938-0905, via email (firstname.lastname@example.org), or visit https://kclasslaw.com/cases/ma/nasdaqcm-pbla/ to learn more.
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.